MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ALEMBIC LIMITED (pharmaceuticals)
- ALEMBIC LIMITED Financial Data
ALEMBIC Fact Sheet (ALMC)
Learn: How to Potentially Accumulate Rs 7 Crore in Wealth Over the Long-term
Here is the latest financial fact sheet of ALEMBIC. For more details, see the ALEMBIC quarterly results and ALEMBIC share price and chart. For a sector overview, read our pharmaceuticals sector report.
ALEMBIC Price History
| % ch | % | -1.5 |
| No. of shares | m | 553.80 |
| % ch week | % | -4.6 |
| % ch 1-mth | % | 22.5 |
| % ch 12-mth | % | 158.4 |
| 52 week H/L | Rs | 143.3/47.2 |
ALEMBIC Financials
| No. of Mths Year Ending |
12 Mar-14 |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| ALEMBIC EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 18 | 70 | 53 | 46 | 72 | |
| Low | Rs | 7 | 16 | 29 | 32 | 34 | |
| Sales per share (Unadj.) | Rs | 5.8 | 5.4 | 4.7 | 5.3 | 4.7 | |
| Earnings per share (Unadj.) | Rs | 1.1 | 4.0 | 8.8 | 5.4 | 6.1 | |
| Diluted earnings per share | Rs | 0.5 | 1.9 | 4.2 | 2.6 | 2.9 | |
| Cash flow per share (Unadj.) | Rs | 1.2 | 4.2 | 9.0 | 5.6 | 6.2 | |
| Dividends per share (Unadj.) | Rs | 0.15 | 0.15 | 0.15 | 0.20 | 0.20 | |
| Adj. dividends per share | Rs | 0.07 | 0.07 | 0.07 | 0.10 | 0.10 | |
| Dividend yield (eoy) | % | 1.2 | 0.3 | 0.4 | 0.5 | 0.4 | |
| Book value per share (Unadj.) | Rs | 8.6 | 19.8 | 27.7 | 34.1 | 40.7 | |
| Adj. book value per share | Rs | 4.2 | 9.5 | 13.4 | 16.5 | 19.6 | |
| Shares outstanding (eoy) | m | 267.03 | 267.03 | 267.03 | 267.03 | 267.03 | |
| Bonus/Rights/Conversions | B1:1 | - | - | - | - | ||
| Price / Sales ratio | x | 2.1 | 8.0 | 8.7 | 7.5 | 11.3 | |
| Avg P/E ratio | x | 11.2 | 10.8 | 4.7 | 7.2 | 8.7 | |
| P/CF ratio (eoy) | x | 10.4 | 10.2 | 4.6 | 7.0 | 8.5 | |
| Price / Book Value ratio | x | 1.4 | 2.2 | 1.5 | 1.2 | 1.3 | |
| Dividend payout | % | 13.6 | 3.8 | 1.7 | 3.7 | 3.3 | |
| Avg Mkt Cap | Rs m | 3,298 | 11,469 | 10,962 | 10,521 | 14,139 | |
| No. of employees | `000 | NA | NA | NA | NA | NA | |
| Total wages/salary | Rs m | 273 | 270 | 238 | 228 | 207 | |
| Avg. sales/employee | Rs Th | NM | NM | NM | NM | NM | |
| Avg. wages/employee | Rs Th | NM | NM | NM | NM | NM | |
| Avg. net profit/employee | Rs Th | NM | NM | NM | NM | NM | |
| ALEMBIC INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,536 | 1,439 | 1,260 | 1,403 | 1,255 | |
| Other income | Rs m | 158 | 208 | 264 | 310 | 370 | |
| Total revenues | Rs m | 1,694 | 1,647 | 1,524 | 1,713 | 1,625 | |
| Gross profit | Rs m | 223 | 95 | 83 | 67 | 111 | |
| Depreciation | Rs m | 23 | 60 | 61 | 51 | 38 | |
| Interest | Rs m | 23 | 8 | 0 | 2 | 2 | |
| Profit before tax | Rs m | 335 | 235 | 285 | 324 | 442 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 825 | 2,096 | 1,179 | 1,212 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | -32 | -58 | 0 | |
| Tax | Rs m | 39 | -7 | 6 | -9 | 24 | |
| Profit after tax | Rs m | 295 | 1,066 | 2,343 | 1,454 | 1,630 | |
| Gross profit margin | % | 14.5 | 6.6 | 6.6 | 4.8 | 8.9 | |
| Effective tax rate | % | 11.8 | -2.9 | 2.1 | -2.6 | 5.4 | |
| Net profit margin | % | 19.2 | 74.1 | 185.9 | 103.6 | 129.8 | |
| ALEMBIC BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 1,543 | 1,609 | 1,689 | 1,913 | 1,867 | |
| Current liabilities | Rs m | 907 | 533 | 486 | 683 | 591 | |
| Net working cap to sales | % | 41.4 | 74.8 | 95.4 | 87.6 | 101.6 | |
| Current ratio | x | 1.7 | 3.0 | 3.5 | 2.8 | 3.2 | |
| Inventory Days | Days | 248 | 214 | 217 | 132 | 94 | |
| Debtors Days | Days | 66 | 122 | 81 | 56 | 74 | |
| Net fixed assets | Rs m | 1,800 | 1,715 | 1,624 | 1,716 | 1,791 | |
| Share capital | Rs m | 534 | 534 | 534 | 534 | 534 | |
| "Free" reserves | Rs m | 874 | 3,839 | 5,960 | 8,580 | 10,324 | |
| Net worth | Rs m | 2,307 | 5,278 | 7,404 | 9,114 | 10,858 | |
| Long term debt | Rs m | 331 | 354 | 104 | 18 | 41 | |
| Total assets | Rs m | 3,562 | 6,192 | 8,010 | 9,924 | 11,591 | |
| Interest coverage | x | 15.4 | 29.3 | 950.7 | 203.8 | 260.9 | |
| Debt to equity ratio | x | 0.1 | 0.1 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.4 | 0.2 | 0.2 | 0.1 | 0.1 | |
| Return on assets | % | 8.9 | 17.4 | 29.3 | 14.7 | 14.1 | |
| Return on equity | % | 12.8 | 20.2 | 31.6 | 16.0 | 15.0 | |
| Return on capital | % | 13.6 | 19.0 | 31.3 | 15.8 | 15.2 | |
| Exports to sales | % | 7.7 | 14.3 | 2.9 | 0.7 | 1.5 | |
| Imports to sales | % | 3.4 | 2.5 | 28.9 | 25.4 | 21.0 | |
| Exports (fob) | Rs m | 118 | 205 | 37 | 10 | 19 | |
| Imports (cif) | Rs m | 52 | 37 | 364 | 356 | 263 | |
| Fx inflow | Rs m | 118 | 205 | 37 | 10 | 19 | |
| Fx outflow | Rs m | 63 | 42 | 365 | 357 | 264 | |
| Net fx | Rs m | 55 | 163 | -328 | -346 | -244 | |
| ALEMBIC CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | -102 | 220 | 346 | 516 | 236 | |
| From Investments | Rs m | 178 | 47 | -48 | -467 | -224 | |
| From Financial Activity | Rs m | -79 | -250 | -301 | -50 | -27 | |
| Net Cashflow | Rs m | -3 | 17 | -3 | 0 | -15 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Chirayu R. Amin (MD) | COMP SEC: Chirag K. Shukla | YEAR OF INC: 1907 | BSE CODE: 506235 | FV (Rs): 2 | DIV YIELD (%): 0.1 |
More Pharmaceuticals Company Fact Sheets: ALEMBIC PHARMA WOCKHARDT PROCTER & GAMBLE HEALTH BIOCON UNICHEM LAB
Compare ALEMBIC With: ALEMBIC PHARMA WOCKHARDT PROCTER & GAMBLE HEALTH BIOCON UNICHEM LAB
Compare ALEMBIC With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Views on news
ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)
May 14, 2021The company's board recommended a final dividend of Rs 25 for financial year 2020-21.
What's Behind the Rally in Pharma Stocks? (Views On News)
May 11, 2021The second wave of Covid has given a new lease of life to pharma stocks.
Why Did Alembic Pharma Shares Fall Today? (Views On News)
May 5, 2021Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.
ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)
Aug 27, 2019 | Updated on Aug 27, 2019For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsMost Popular
My Secret to Find Breakthrough Stocks (Fast Profits Daily)
May 7, 2021I've used this trading technique for many years with great success. I'm sharing it with you today.
Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)
May 6, 2021Why are markets discounting the economic impact of Covid?
The Worst Sector in the Market (Fast Profits Daily)
May 11, 2021The worst sector in the stock market according to the charts.
The Key to Profit from India's EV Revolution (Profit Hunter)
May 7, 2021Stocks you must consider investing in before buying your first electric vehicle.
MoreOUR TOP 5 IDEAS
- FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK ALEMBIC
- Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC
ALEMBIC - ACTAVIS COMPARISON
COMPARE ALEMBIC WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.